Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06713603 · ClinicalTrials.gov registry record · NA

Technology Assisted Motivational Interviewing

A NA study of Smoking Cessation and Smoking, sponsored by University of California, San Francisco.

Recruiting
Registry status
NA
Development phase
440
Enrollment target
2
Study locations

NCT06713603: Recruiting NA study of Smoking Cessation and Smoking, sponsored by University of California, San Francisco.

NCT06713603 is a NA study of Smoking Cessation and Smoking that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 440 participants, roughly in line with the 472-participant average among 188 other Smoking Cessation trials with a reported enrollment target. The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06713603, a NA study of Smoking Cessation and Smoking, is actively recruiting participants, sponsored by University of California, San Francisco.

RECRUITING
Registry status
NA
Development phase
440 participants
Enrollment target
2
Study locations

Study Summary

Building on our successful pilot work to develop a Motivational Interviewing (MI)-capable chatbot and cessation coach, the investigators propose to address the problems of intrinsic motivation and social barriers to smoking cessation by evaluating a highly scalable and easily accessible digital-coaching intervention that 1) promotes readiness to change using a technology-assisted MI (TAMI) chatbot, 2) provides compelling and accessible multilingual education about smoking cessation tools, and 3) develops a tailored quit plan addressing social barriers to treatment initiation and sustainment.

Primary Outcome

The primary clinical outcome is 7-day point prevalence abstinence (PPA) from smoking at 6-months. Abstinence will be biochemically verified with salivary cotinine. To maximize the validity of our primary abstinence outcome, the investigators will require any participant in who reports abstinence at 6-month to complete salivary cotinine bio-verification using a mailed, commercially available test kit. Participants will be instructed to electronically send two photos - one of them giving a saliva

Interventions

  • BEHAVIORAL TAMI Coach

Study Locations (2)

California

  • San Francisco General Hospital - San Francisco
  • UCSF Adult Primary Care Mt. Zion Clinic - San Francisco

Trial Details

FieldValue
Enrollment Target 440 participants
Start Date 2025-09-22
Est. Completion 2027-05-31
Phase NA

What NCT06713603 shows while recruiting

NCT06713603 is an interventional study that assigns participants to a tested intervention. The registered 440 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 472-participant average among 188 other Smoking Cessation trials with a reported enrollment target.

The record links to 2 conditions, with Smoking Cessation appearing as the primary indexed condition, and to 1 intervention - of which TAMI Coach is the first listed.

NCT06713603 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT06713603 about?

NCT06713603 is a clinical study titled "Technology Assisted Motivational Interviewing". Building on our successful pilot work to develop a Motivational Interviewing (MI)-capable chatbot and cessation coach, the investigators propose to address the problems of intrinsic motivation and social barriers to smoking cessation by evaluating a highly scalable and easily accessible digital-coac...

What is the current status of trial NCT06713603?

This trial is currently recruiting. It is a NA study. The enrollment target is 440 participants. The study started on 2025-09-22. Estimated completion is 2027-05-31.

What conditions does trial NCT06713603 study?

This clinical trial studies the following conditions: Smoking Cessation, Smoking.

What interventions are being tested in trial NCT06713603?

The interventions under investigation include: TAMI Coach (BEHAVIORAL).

Who is sponsoring clinical trial NCT06713603?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06713603 being conducted?

This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Smoking Cessation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06713603's enrollment target sits among peer trials

440 61st of 188 higher than 127 of 188 other Smoking Cessation trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Smoking Cessation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05114538 · 440 participants · NA

    Improving the Part C Early Intervention Service Delivery System for Children with ASD

  • NCT05117619 · 440 participants · NA

    The HOME Program for Individuals With Traumatic Brain Injury and Family Members

  • NCT05602194 · 440 participants · Phase 3

    Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma

  • NCT05624879 · 440 participants · NA

    Accelerated Resolution Therapy for Early Maladaptive Grief

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06713603, the US trial registry maintained by the National Library of Medicine. NCT06713603 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.